Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth and Spread of Medulloblastoma

(2013) Matija Snuderl et al.   CELL

Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2013) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment

(2012) Douglas Hanahan et al.   CANCER CELL

Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate

(2012) Patrick S. Ward et al.   CANCER CELL

Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1

(2012) Yousuke Nakai et al.   CANCER SCIENCE

SnapShot: Tumor Angiogenesis

(2012) Rakesh K. Jain et al.   CELL

Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas

(2012) M. Hidalgo et al.   CLINICAL CANCER RESEARCH

The Biology of Brain Metastasis

(2012) R. R. Langley et al.   CLINICAL CHEMISTRY

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

(2012) Diether Lambrechts et al.   LANCET ONCOLOGY

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

(2012) Vikash P. Chauhan et al.   Nature Nanotechnology

Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)

(2012) Chandrajit P. Raut et al.   PLoS One

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer

(2012) Jeffrey A. Meyerhardt et al.   PLoS One

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology

(2012) S. Goel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors

(2012) T. Stylianopoulos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases

(2012) D. P. Kodack et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor-targeted TNF  stabilizes tumor vessels and enhances active immunotherapy

(2012) A. Johansson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGF-  blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma

(2012) J. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

(2012) Gregg L. Semenza   TRENDS IN PHARMACOLOGICAL SCIENCES

Reappraising antiangiogenic therapy for breast cancer

(2011) Robert S. Kerbel   BREAST

Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion

(2011) A. G. Sorensen et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

CXCL12 (SDF1 )-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

(2011) D. G. Duda et al.   CLINICAL CANCER RESEARCH

TGF-β Blockade Controls Ascites by Preventing Abnormalization of Lymphatic Vessels in Orthotopic Human Ovarian Carcinoma Models

(2011) Shan Liao et al.   CLINICAL CANCER RESEARCH

Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination

(2011) Daniel Keizman et al.   EUROPEAN JOURNAL OF CANCER

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

(2011) Andrea Facciabene et al.   NATURE

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

The lymphatic vasculature in disease

(2011) Kari Alitalo   NATURE MEDICINE

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Mechanical compression drives cancer cells toward invasive phenotype

(2011) J. M. Tse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors

(2011) B. Diop-Frimpong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Impaired lymphatic contraction associated with immunosuppression

(2011) S. Liao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of renin–angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine

(2010) Y Nakai et al.   BRITISH JOURNAL OF CANCER

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Macrophage Diversity Enhances Tumor Progression and Metastasis

(2010) Bin-Zhi Qian et al.   CELL

"Contextual" Synthetic Lethality and/or Loss of Heterozygosity: Tumor Hypoxia and Modification of DNA Repair

(2010) N. Chan et al.   CLINICAL CANCER RESEARCH

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

(2010) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models

(2010) DAI FUKUMURA et al.   MICROCIRCULATION

Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy

(2010) Napoleone Ferrara   NATURE MEDICINE

In vivo wide-area cellular imaging by side-view endomicroscopy

(2010) Pilhan Kim et al.   NATURE METHODS

Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

(2010) D. G. Duda et al.   ONCOLOGIST

Heterogeneity of the Tumor Vasculature

(2010) Janice Nagy et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Endothelial Nitric Oxide Synthase Mediates Lymphangiogenesis and Lymphatic Metastasis

(2009) J. Lahdenranta et al.   CANCER RESEARCH

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1 , CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

(2009) L. Xu et al.   CANCER RESEARCH

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization

(2009) Massimiliano Mazzone et al.   CELL

Pathways mediating VEGF-independent tumor angiogenesis

(2009) Napoleone Ferrara   CYTOKINE & GROWTH FACTOR REVIEWS

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

(2009) Stefan Wilop et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

(2009) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging

(2009) Benjamin J Vakoc et al.   NATURE MEDICINE

In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts

(2009) Jean Y Perentes et al.   NATURE METHODS

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2

(2009) Scott R. Plotkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Taming Vessels to Treat Cancer

(2009) Rakesh K. Jain   SCIENTIFIC AMERICAN

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

(2008) T. P. Padera et al.   MOLECULAR CANCER THERAPEUTICS

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

(2008) Juliana Hamzah et al.   NATURE

Perivascular nitric oxide gradients normalize tumor vasculature

(2008) Satoshi Kashiwagi et al.   NATURE MEDICINE